Archangels secures £12m co-investment agreement with British Business Investments

Archangels, a leading business angel syndicate investing in early-stage Scottish life sciences and technology companies, is bolstering its funding fire power after securing a £12m co-investment agreement with British Business Investments via its Regional Angels Programme.

The deal will provide the Edinburgh-based syndicate with additional capital to fuel the success of Scotland’s next generation of entrepreneurs and innovators.

Archangels will deploy the capital from British Business Investments, a wholly owned commercial subsidiary of the British Business Bank, alongside syndicate funding across all of its investment activity.

Operating for over 30 years, Archangels is deeply committed to its long-term role in maximising investor returns, building and nurturing successful businesses and helping Scotland prosper. Archangels has invested over £160 million in the most innovative early-stage companies, with disruptive technology, protectable IP and the potential to scale globally. In recent years Archangels has enjoyed a number of significant exits, including the sale of medical AI business, Blackford Analysis, to Bayer Pharma earlier in the year and the sale of optical platform business, Optoscribe, to Intel Corporation in 2022.

As lead investor, Archangels regularly invests alongside a range of co-investment partners including Scottish Enterprise, other angel syndicates and VCs. Recent investments include participation in a £2.2M funding round to support Edinburgh-based Bioliberty.